The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
Abstract Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improp...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2011-09, Vol.29 (42), p.7267-7275 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7275 |
|---|---|
| container_issue | 42 |
| container_start_page | 7267 |
| container_title | Vaccine |
| container_volume | 29 |
| creator | Coller, Beth-Ann G Clements, David E Bett, Andrew J Sagar, Sangeetha L Ter Meulen, Jan H |
| description | Abstract Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improper folding, but the use of the Drosophila S2 cell expression system provided a mechanism to overcome these limitations. The truncated dengue envelope proteins (DEN-80E) for all four dengue virus types are expressed in the S2 system at high levels and have been shown to maintain native-like conformation. The DEN-80E proteins are potent immunogens when formulated with a variety of adjuvants, inducing high titer virus neutralizing antibody responses and demonstrating protection in both mouse and non-human primate models. Tetravalent vaccine formulations have shown no evidence of immune interference between the four DEN-80E antigens in preclinical models. Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review. |
| doi_str_mv | 10.1016/j.vaccine.2011.07.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3179979</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X11010425</els_id><sourcerecordid>1678522381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5951-41b31bae4219d37fd60a1a539af7a060faeea0562d9682805d0c6e6c7c86d3633</originalsourceid><addsrcrecordid>eNqFkk1vEzEQhlcIREPhJ4BW4gCXhBl7_XVphSq-pEocKBI3y-udpA4bO6x3I_Xf45BQoAd6siw_7zuembeqniMsEFC-WS92zvsQacEAcQFqAQwfVDPUis-ZQP2wmgGTzbxB-HZSPcl5DQCCo3lcnTBUSkmuZlW8uqa6ox31abuhONZpWQ_k06YN0ZVrntophrGm-AuheesydfWxdq7HVG-HNJIfa7dyIeaxuMXVRPUuDFOuQ-wmXwRdyFSUT6tHS9dnenY8T6uv799dXXycX37-8Oni7eXcCyOw_Lnl2DpqGJqOq2UnwaET3LilciBh6YgcCMk6IzXTIDrwkqRXXsuOS85Pq7OD73ZqN9T50tngersdwsYNNza5YP99ieHartLOclTGKFMMXh0NhvRjojzaTcie-t5FSlO2BppGi0bKe0mtNedGCCjk6_-SKJUWjHGNBX15B12naYhlZBYboxGMwX2X4kD5IeU80PK2QQS7T4ld2-Om7D4lFpQtKSm6F39P51b1OxYFOD8AVHa0CzTY7APFsshQwjHaLoV7S5zdcfB9iMG7_jvdUP7Tjc3Mgv2yj-o-qVg8oWGC_wSu_-cE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1498109913</pqid></control><display><type>article</type><title>The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Coller, Beth-Ann G ; Clements, David E ; Bett, Andrew J ; Sagar, Sangeetha L ; Ter Meulen, Jan H</creator><creatorcontrib>Coller, Beth-Ann G ; Clements, David E ; Bett, Andrew J ; Sagar, Sangeetha L ; Ter Meulen, Jan H</creatorcontrib><description>Abstract Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improper folding, but the use of the Drosophila S2 cell expression system provided a mechanism to overcome these limitations. The truncated dengue envelope proteins (DEN-80E) for all four dengue virus types are expressed in the S2 system at high levels and have been shown to maintain native-like conformation. The DEN-80E proteins are potent immunogens when formulated with a variety of adjuvants, inducing high titer virus neutralizing antibody responses and demonstrating protection in both mouse and non-human primate models. Tetravalent vaccine formulations have shown no evidence of immune interference between the four DEN-80E antigens in preclinical models. Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review.</description><identifier>ISSN: 0264-410X</identifier><identifier>ISSN: 1873-2518</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2011.07.021</identifier><identifier>PMID: 21777637</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>adjuvants ; Adjuvants, Immunologic - administration & dosage ; Allergy and Immunology ; Animals ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; antigens ; Cell culture ; Cell Line ; clinical trials ; Dengue ; Dengue - prevention & control ; Dengue fever ; Dengue Vaccines - administration & dosage ; Dengue Vaccines - genetics ; Dengue Vaccines - immunology ; Dengue virus ; Dengue Virus - genetics ; Dengue Virus - immunology ; Drosophila ; E coli ; Gene Expression ; Humans ; Hypotheses ; Infections ; Mice ; neutralization ; neutralizing antibodies ; Primates ; Protein Conformation ; Proteins ; Recombinant ; recombinant proteins ; Subunit ; Vaccine ; Vaccines ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - genetics ; Vaccines, Subunit - immunology ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - genetics ; Vaccines, Synthetic - immunology ; Vector-borne diseases ; Viral Envelope Proteins - genetics ; Viral Envelope Proteins - immunology ; viral load ; Viruses</subject><ispartof>Vaccine, 2011-09, Vol.29 (42), p.7267-7275</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 23, 2011</rights><rights>2011 Elsevier Ltd. All rights reserved. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5951-41b31bae4219d37fd60a1a539af7a060faeea0562d9682805d0c6e6c7c86d3633</citedby><cites>FETCH-LOGICAL-c5951-41b31bae4219d37fd60a1a539af7a060faeea0562d9682805d0c6e6c7c86d3633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X11010425$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21777637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coller, Beth-Ann G</creatorcontrib><creatorcontrib>Clements, David E</creatorcontrib><creatorcontrib>Bett, Andrew J</creatorcontrib><creatorcontrib>Sagar, Sangeetha L</creatorcontrib><creatorcontrib>Ter Meulen, Jan H</creatorcontrib><title>The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improper folding, but the use of the Drosophila S2 cell expression system provided a mechanism to overcome these limitations. The truncated dengue envelope proteins (DEN-80E) for all four dengue virus types are expressed in the S2 system at high levels and have been shown to maintain native-like conformation. The DEN-80E proteins are potent immunogens when formulated with a variety of adjuvants, inducing high titer virus neutralizing antibody responses and demonstrating protection in both mouse and non-human primate models. Tetravalent vaccine formulations have shown no evidence of immune interference between the four DEN-80E antigens in preclinical models. Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review.</description><subject>adjuvants</subject><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>antigens</subject><subject>Cell culture</subject><subject>Cell Line</subject><subject>clinical trials</subject><subject>Dengue</subject><subject>Dengue - prevention & control</subject><subject>Dengue fever</subject><subject>Dengue Vaccines - administration & dosage</subject><subject>Dengue Vaccines - genetics</subject><subject>Dengue Vaccines - immunology</subject><subject>Dengue virus</subject><subject>Dengue Virus - genetics</subject><subject>Dengue Virus - immunology</subject><subject>Drosophila</subject><subject>E coli</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Infections</subject><subject>Mice</subject><subject>neutralization</subject><subject>neutralizing antibodies</subject><subject>Primates</subject><subject>Protein Conformation</subject><subject>Proteins</subject><subject>Recombinant</subject><subject>recombinant proteins</subject><subject>Subunit</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - genetics</subject><subject>Vaccines, Subunit - immunology</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Vaccines, Synthetic - genetics</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Vector-borne diseases</subject><subject>Viral Envelope Proteins - genetics</subject><subject>Viral Envelope Proteins - immunology</subject><subject>viral load</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1vEzEQhlcIREPhJ4BW4gCXhBl7_XVphSq-pEocKBI3y-udpA4bO6x3I_Xf45BQoAd6siw_7zuembeqniMsEFC-WS92zvsQacEAcQFqAQwfVDPUis-ZQP2wmgGTzbxB-HZSPcl5DQCCo3lcnTBUSkmuZlW8uqa6ox31abuhONZpWQ_k06YN0ZVrntophrGm-AuheesydfWxdq7HVG-HNJIfa7dyIeaxuMXVRPUuDFOuQ-wmXwRdyFSUT6tHS9dnenY8T6uv799dXXycX37-8Oni7eXcCyOw_Lnl2DpqGJqOq2UnwaET3LilciBh6YgcCMk6IzXTIDrwkqRXXsuOS85Pq7OD73ZqN9T50tngersdwsYNNza5YP99ieHartLOclTGKFMMXh0NhvRjojzaTcie-t5FSlO2BppGi0bKe0mtNedGCCjk6_-SKJUWjHGNBX15B12naYhlZBYboxGMwX2X4kD5IeU80PK2QQS7T4ld2-Om7D4lFpQtKSm6F39P51b1OxYFOD8AVHa0CzTY7APFsshQwjHaLoV7S5zdcfB9iMG7_jvdUP7Tjc3Mgv2yj-o-qVg8oWGC_wSu_-cE</recordid><startdate>20110923</startdate><enddate>20110923</enddate><creator>Coller, Beth-Ann G</creator><creator>Clements, David E</creator><creator>Bett, Andrew J</creator><creator>Sagar, Sangeetha L</creator><creator>Ter Meulen, Jan H</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7S9</scope><scope>L.6</scope><scope>7X8</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope><scope>5PM</scope></search><sort><creationdate>20110923</creationdate><title>The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease</title><author>Coller, Beth-Ann G ; Clements, David E ; Bett, Andrew J ; Sagar, Sangeetha L ; Ter Meulen, Jan H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5951-41b31bae4219d37fd60a1a539af7a060faeea0562d9682805d0c6e6c7c86d3633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>adjuvants</topic><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>antigens</topic><topic>Cell culture</topic><topic>Cell Line</topic><topic>clinical trials</topic><topic>Dengue</topic><topic>Dengue - prevention & control</topic><topic>Dengue fever</topic><topic>Dengue Vaccines - administration & dosage</topic><topic>Dengue Vaccines - genetics</topic><topic>Dengue Vaccines - immunology</topic><topic>Dengue virus</topic><topic>Dengue Virus - genetics</topic><topic>Dengue Virus - immunology</topic><topic>Drosophila</topic><topic>E coli</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Infections</topic><topic>Mice</topic><topic>neutralization</topic><topic>neutralizing antibodies</topic><topic>Primates</topic><topic>Protein Conformation</topic><topic>Proteins</topic><topic>Recombinant</topic><topic>recombinant proteins</topic><topic>Subunit</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - genetics</topic><topic>Vaccines, Subunit - immunology</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Vaccines, Synthetic - genetics</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Vector-borne diseases</topic><topic>Viral Envelope Proteins - genetics</topic><topic>Viral Envelope Proteins - immunology</topic><topic>viral load</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coller, Beth-Ann G</creatorcontrib><creatorcontrib>Clements, David E</creatorcontrib><creatorcontrib>Bett, Andrew J</creatorcontrib><creatorcontrib>Sagar, Sangeetha L</creatorcontrib><creatorcontrib>Ter Meulen, Jan H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>MEDLINE - Academic</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coller, Beth-Ann G</au><au>Clements, David E</au><au>Bett, Andrew J</au><au>Sagar, Sangeetha L</au><au>Ter Meulen, Jan H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2011-09-23</date><risdate>2011</risdate><volume>29</volume><issue>42</issue><spage>7267</spage><epage>7275</epage><pages>7267-7275</pages><issn>0264-410X</issn><issn>1873-2518</issn><eissn>1873-2518</eissn><abstract>Abstract Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improper folding, but the use of the Drosophila S2 cell expression system provided a mechanism to overcome these limitations. The truncated dengue envelope proteins (DEN-80E) for all four dengue virus types are expressed in the S2 system at high levels and have been shown to maintain native-like conformation. The DEN-80E proteins are potent immunogens when formulated with a variety of adjuvants, inducing high titer virus neutralizing antibody responses and demonstrating protection in both mouse and non-human primate models. Tetravalent vaccine formulations have shown no evidence of immune interference between the four DEN-80E antigens in preclinical models. Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>21777637</pmid><doi>10.1016/j.vaccine.2011.07.021</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2011-09, Vol.29 (42), p.7267-7275 |
| issn | 0264-410X 1873-2518 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3179979 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | adjuvants Adjuvants, Immunologic - administration & dosage Allergy and Immunology Animals Antibodies, Neutralizing - blood Antibodies, Viral - blood antigens Cell culture Cell Line clinical trials Dengue Dengue - prevention & control Dengue fever Dengue Vaccines - administration & dosage Dengue Vaccines - genetics Dengue Vaccines - immunology Dengue virus Dengue Virus - genetics Dengue Virus - immunology Drosophila E coli Gene Expression Humans Hypotheses Infections Mice neutralization neutralizing antibodies Primates Protein Conformation Proteins Recombinant recombinant proteins Subunit Vaccine Vaccines Vaccines, Subunit - administration & dosage Vaccines, Subunit - genetics Vaccines, Subunit - immunology Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - genetics Vaccines, Synthetic - immunology Vector-borne diseases Viral Envelope Proteins - genetics Viral Envelope Proteins - immunology viral load Viruses |
| title | The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A04%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20development%20of%20recombinant%20subunit%20envelope-based%20vaccines%20to%20protect%20against%20dengue%20virus%20induced%20disease&rft.jtitle=Vaccine&rft.au=Coller,%20Beth-Ann%20G&rft.date=2011-09-23&rft.volume=29&rft.issue=42&rft.spage=7267&rft.epage=7275&rft.pages=7267-7275&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2011.07.021&rft_dat=%3Cproquest_pubme%3E1678522381%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1498109913&rft_id=info:pmid/21777637&rft_els_id=S0264410X11010425&rfr_iscdi=true |